Hypothesizing that histone deacetylase inhibitors can be used to reverse multiple drug resistance

Medical Hypotheses

Volumn 74, Issue 1, 2010, Pages 92-94

  Jiang, Zhi Ping ^a   Xu, Ping ^b   Wang, Guan Ping ^a   Zhao, Xie Lan ^a   Chen, Fang Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIRICODAR; CINCHONINE; CYCLOSPORIN A; DEPSIPEPTIDE; DEXVERAPAMIL; ETOPOSIDE; GLYCOPROTEIN P; HISTONE DEACETYLASE INHIBITOR; LANIQUIDAR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; QUINIDINE; TRICHOSTATIN A; VALSPODAR; VERAPAMIL; VORINOSTAT; ZOSUQUIDAR;

ARTICLE; CANCER RESISTANCE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG SENSITIVITY; DRUG TARGETING; EPIGENETICS; FIRST PASS EFFECT; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL LINE, TUMOR; DNA METHYLATION; DRUG RESISTANCE, MULTIPLE; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; MODELS, THEORETICAL; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 70450242724     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.07.036     Document Type: Article

References (25)

1. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38 7-8 (2008) 802-832
2. Nobili S., Landini I., Giglioni B., and Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7 7 (2006) 861-879
3. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 1 (2004) 13-33
4. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97 7 (2000) 3473-3478
5. Choudhuri S., and Klaassen C.D. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25 4 (2006) 231-259
6. Chinn L.W., and Kroetz D.L. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 81 2 (2007) 265-269
7. Woodahl E.L., and Ho R.J. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5 1 (2004) 11-19
8. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., Zahurak M., Piantadosi S., Walsh P.C., et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64 6 (2004) 1975-1986
9. Garcia-Manero G., Daniel J., Smith T.L., Kornblau S.M., Lee M.S., Kantarjian H.M., et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8 7 (2002) 2217-2224
10. Kantharidis P., El-Osta A., de Silva M., Wall D.M., Hu X.F., Slater A., et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 3 11 (1997) 2025-2032
11. Kusaba H., Nakayama M., Harada T., et al. Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem 262 3 (1999) 924-932
12. El-Osta A., Kantharidis P., Zalcberg J.R., and Wolffe A.P. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 22 6 (2002) 1844-1857
13. Desiderato L., Davey M.W., and Piper A.A. Demethylation of the human MDR1 5' region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat Cell Mol Genet 23 6 (1997) 391-400
14. Baker E.K., Johnstone R.W., Zalcberg J.R., and El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24 54 (2005) 8061-8075
15. Jiang Z.P., Xu P., Liu R.R., et al. Correlation between MDR1 methylation status in the promoter region and MDR1 genetic polymorphism in 194 healthy Chinese Han subjects. Pharmacogenomics 9 12 (2008) 1801-1808
16. Takane H., Kobayashi D., Hirota T., et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 311 3 (2004) 1179-1187
17. Xiao J.J., Huang Y., Dai Z., et al. Chemoresistance to depsipeptide FK228 [(E)-(1S, 4S, 10S, 21R)-7-[(Z)-ethylidene]-4, 21-diisopropyl-2-oxa-12, 13-dithia-5, 8, 20, 23-tetraazabicyclo[8,7,6]-tricos-16-ene-3, 6, 9, 22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 314 1 (2005) 467-475
18. Chen K.G., Wang Y.C., Schaner M.E., et al. Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line. Cancer Res 65 20 (2005) 9388-9397
19. Ruefli A.A., Tainton K.M., Darcy P.K., Smyth M.J., and Johnstone R.W. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Cell Death Differ 9 11 (2002) 1266-1272
20. El-Khoury V., Breuzard G., Fourré N., and Dufer J. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. Br J Cancer 97 4 (2007) 562-573
21. Kimchi-Sarfaty C., Oh J.M., Kim I.W., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 5811 (2007) 525-528
22. Robey R.W., Zhan Z., Piekarz R.L., Kayastha G.L., Fojo T., and Bates S.E. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 12 5 (2006) 1547-1555
23. Yu X.Y., Lin S.G., Zhou Z.W., Chen X., et al. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge. Curr Drug Metab 8 4 (2007 May) 325-340
24. Baumert C., and Hilgeroth A. Recent advances in the development of P-gp inhibitors. Anticancer Agents Med Chem 9 4 (2009) 415-436
25. Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13 16 (2006) 1859-1876